Nimbus Discovery and Monsanto Announce Collaboration

  Nimbus Discovery and Monsanto Announce Collaboration

         Companies Will Focus Efforts on Developing Novel Fungicides

Business Wire

CAMBRIDGE, Mass. and ST. LOUIS -- June 27, 2013

Nimbus Discovery, LLC, a biotechnology company discovering novel approaches
for previously inaccessible disease targets, and Monsanto Company, today
announced a collaboration to develop broad-spectrum fungicides, with new modes
of action, that help farmers control diseases and promote overall plant

Fungal infections appear as rusts, leaf spots and blights on a range of
important food crops and are estimated to result in significant global crop
losses each year.

Under the terms of the agreement, a jointly-owned entity will be created that
has access to Nimbus’ validated computational platform. Nimbus, with its
innovative research tools together with Monsanto’s agricultural testing
capabilities will co-develop agricultural fungicides. Monsanto will have
access to applications within agriculture and Nimbus will retain rights for
all other applications. Financial terms were not disclosed.

“Working with Monsanto gives Nimbus a unique opportunity to showcase its
integrated computational chemistry and drug discovery strengths in the global
agricultural marketplace,” said Rosana Kapeller, M.D., Ph.D., Chief Scientific
Officer of Nimbus. “This partnership demonstrates the broad applicability of
the Nimbus platform and the ability of the Nimbus team to extract the greatest
value from our scientific assets.”

Monsanto’s corporate venture group has an on-going strategic alliance with
Atlas Venture, founder of Nimbus Discovery, to explore co-investment
opportunities in early-stage life sciences technology companies. This
announcement is an investment supported by the alliance.

“Part of our commitment to bringing new technologies to agriculture is
identifying innovators we can work with to deliver solutions for our farmer
customers,” said Steve Padgette, Monsanto R&D investment strategy lead.
“Nimbus is breaking new ground with promising and novel work that has strong
potential to be applied in agriculture. We look forward to working with them
through this new collaboration, which will complement our own research

About Nimbus

Nimbus Discovery, a biotechnology company, harnesses cutting-edge
computational technologies to uncover breakthroughs in small molecule
pharmacology. Nimbus focuses on medically important and highly sought-after
disease targets that have proven inaccessible to traditional industry
approaches. Nimbus’ robust pre-clinical pipeline includes novel agents for the
treatment of cancer, metabolic disease and inflammation. The company is
organized as a constellation of small, nimble teams of experienced
drug-hunters deployed across program-focused subsidiary companies. Each team
is freed from conventional barriers to scientific success, chartered to create
solutions, and geared for program asset deals with leading pharmaceutical
companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and
apply a physics-based approach that establishes a new standard for rational
drug design. Nimbus is backed by world-class life science investors, including
Atlas Venture, SR One, Lilly Ventures and Bill Gates. For more information
please visit

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions
and agricultural products that improve farm productivity and food quality.
Monsanto remains focused on enabling both small-holder and large-scale farmers
to produce more from their land while conserving more of our world's natural
resources such as water and energy. To learn more about our business and our
commitments, please visit: Follow our business on Twitter^®
at, on the company blog, Beyond the Rows^® at, or subscribe to our News Release RSS Feed.

Monsanto Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are "forward-looking statements,"
such as statements concerning the company's anticipated financial results,
current and future product performance, regulatory approvals, business and
financial plans and other non-historical facts. These statements are based on
current expectations and currently available information. However, since these
statements are based on factors that involve risks and uncertainties, the
company's actual performance and results may differ materially from those
described or implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, among others: continued
competition in seeds, traits and agricultural chemicals; the company's
exposure to various contingencies, including those related to intellectual
property protection, regulatory compliance and the speed with which approvals
are received, and public acceptance of biotechnology products; the success of
the company's research and development activities; the outcomes of major
lawsuits and the previously-announced SEC investigation; developments related
to foreign currencies and economies; successful operation of recent
acquisitions; fluctuations in commodity prices; compliance with regulations
affecting our manufacturing; the accuracy of the company's estimates related
to distribution inventory levels; the company's ability to fund its short-term
financing needs and to obtain payment for the products that it sells; the
effect of weather conditions, natural disasters and accidents on the
agriculture business or the company's facilities; and other risks and factors
detailed in the company's most recent Form 10-K Report to the SEC. Undue
reliance should not be placed on these forward-looking statements, which are
current only as of the date of this release. The company disclaims any current
intention or obligation to update any forward-looking statements or any of the
factors that may affect actual results.


Nimbus Discovery LLC
Jonathan Montagu, +1-617-588-2600
Vice President, Business Development & Operations
Suda Communications LLC
Maureen L. Suda (Media), +1-585-387-9248
Monsanto Company
Monsanto Public Affairs
Sara Miller, 314-694-5824
Press spacebar to pause and continue. Press esc to stop.